Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in atrial fibrillation

Stroke

Volumn 48, Issue 1, 2017, Pages 159-166

  Hernandez, Inmaculada ^a   Zhang, Yuting ^b   Brooks, Maria M ^b   Chin, Paul K L ^c   Saba, Samir ^d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

anticoagulants; atrial fibrillation; dabigatran; hemorrhage; stroke

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN ISCHEMIA; CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; DISEASE ASSOCIATION; DRUG SUBSTITUTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; PATIENT SAFETY; PRIORITY JOURNAL; RECURRENT DISEASE; VERY ELDERLY; CHEMICALLY INDUCED; COHORT ANALYSIS; EPIDEMIOLOGY; HEMORRHAGE; MEDICAID; MEDICARE; MORTALITY; TREATMENT OUTCOME; TRENDS; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; COHORT STUDIES; DABIGATRAN; FEMALE; HEMORRHAGE; HUMANS; MALE; MEDICAID; MEDICARE; TREATMENT OUTCOME; UNITED STATES; WARFARIN;

EID: 85002062845     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.116.015150     Document Type: Article

References (14)

1. Hart RG, Pearce LA, Aguilar MI. Meta-Analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857-867
2. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138: 1093-1100 doi: 10.1378/chest.10-0134
3. Qureshi W, Mittal C, Patsias I, Garikapati K, Kuchipudi A, Cheema G, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol. 2014; 113: 662-668 doi: 10.1016/j.amjcard.2013.10.044
4. Staerk L, Lip GY, Olesen JB, Fosbøl EL, Pallisgaard JL, Bonde AN, et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ. 2015; 351: h5876
5. Sengupta N, Feuerstein JD, Patwardhan VR, Tapper EB, Ketwaroo GA, Thaker AM, et al. The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. Am J Gastroenterol. 2015; 110: 328-335 doi: 10.1038/ajg. 2014.398
6. Nielsen PB, Larsen TB, Skjøth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a Nationwide Cohort Study. Circulation. 2015; 132: 517-525 doi: 10.1161/CIRCULATIONAHA.115.015735
7. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137: 263-272 doi: 10.1378/chest.09-1584
8. Hernandez I. Time to reconsider dabigatran 110 mg in the USA. Am J Cardiovasc Drugs. 2015; 15: 307-309 doi: 10.1007/s40256-015-0137-0
9. Center for Medicare and Medicaid Services Chronic Conditions Data Warehouse. 27 chronic condition algorithm 2014. https://www.ccwdata. org/cs/groups/public/documents/document/ccw-condition-categories. pdf. Accessed February 22, 2015
10. Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015; 175: 18-24 doi: 10.1001/jamainternmed.2014.5398
11. Thigpen JL, Dillon C, Forster KB, Henault L, Quinn EK, Tripodis Y, et al. Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2015; 8: 8-14 doi: 10.1161/CIRCOUTCOMES.113.000371
12. Lichtman JH, Jones SB, Watanabe E, Allen NB, Wang Y, Howard VJ, et al. Elderly women have lower rates of stroke, cardiovascular events, and mortality after hospitalization for transient ischemic attack. Stroke. 2009; 40: 2116-2122 doi: 10.1161/STROKEAHA.108.543009
13. Pollack CV Jr, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S, et al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015; 114: 198-205 doi: 10.1160/TH15-03-0192.
14. Hernandez I, Zhang Y. Risk of bleeding with dabigatran in 2010-2011 Medicare data. JAMA Intern Med. 2015; 175: 1245-1247 doi: 10.1001/jamainternmed.2015.1299